Analysts have put a $92 price target on Viking Therapeutics, but reaching it depends on trial data and launch timing lining up in the months ahead. Eli Lilly's stock crossed a trillion dollars in market value today, and a UK study found Ozempic and Wegovy users had far fewer asthma attacks. A Connecticut drugmaker is betting on an inhaled alternative, while employers look for sustainable ways to cover this class of drugs. Each story asks what has to happen next before this momentum becomes real.
That $92 price target on Viking Therapeutics carries real conditions attached. Analysts base it on a series of milestones lining up correctly: clean trial results, a launch that lands on schedule, and a market willing to keep backing a challenger to Lilly and Novo Nordisk. If any of those pieces slips, the valuation case gets harder to defend. For investors watching Viking as a possible alternative in this market, the stock's upside depends less on what the company has already shown and more on what it still has to prove.
Eli Lilly's climb to a trillion dollars in market value puts a sharper point on that same question of timing. The company got there on the strength of its GLP-1 franchise, and that scale is exactly why some investors are asking whether the easy gains have already happened. A trillion-dollar valuation does not mean the stock is finished moving, but it does mean new buyers are paying for growth that has, in large part, already arrived. Anyone considering a position now would do well to weigh that against companies like Viking, where the growth, if it comes, is still ahead of the stock rather than behind it.
Employers face their own version of a timing problem, since GLP-1 coverage costs have made this benefit hard to sustain year over year. A new whitepaper argues that captive insurance, where a company or group of companies self-funds and shares risk rather than buying a fully insured plan, offers one way to keep offering these drugs without costs spiraling. The appeal is that it gives employers more control over how claims are managed and priced over time. For HR and benefits teams under pressure to keep GLP-1 coverage in place, this is a structural option worth discussing with a broker or actuary, rather than a guarantee that costs will fall.
On the patient side, a UK records study adds a new data point to the drugs' effects beyond weight and blood sugar. Researchers found that people taking Ozempic or Wegovy had nearly 40 percent fewer asthma attacks compared with those not on the drugs. The study does not establish why, but it fits a growing pattern of GLP-1 drugs showing benefits in conditions connected to inflammation and metabolic health. For patients managing both diabetes or obesity and asthma, this is worth raising with a doctor, though it is not a reason to change asthma treatment on its own.
That same interest in what these drugs can do beyond weight loss extends to how they are delivered. A Connecticut drugmaker has partnered on developing an inhaled weight-loss treatment, aiming to give patients an alternative to weekly injections. If it succeeds, an inhaled option could appeal to people who avoid GLP-1 treatment because of needle aversion or the logistics of injections. Inhaled delivery for a drug class built on injections is a real technical challenge, so this is a development worth watching rather than something patients should expect soon.
Across these stories, the common thread is patience. Viking's valuation, Lilly's next move, employer coverage strategies, and the search for new ways to deliver these drugs all rest on developments that have not fully played out yet. Readers weighing a Viking or Lilly position should look at the specific trial and launch dates that these price targets and market caps assume, rather than the headline numbers themselves. And if you are an employer or benefits manager, it is worth asking your broker directly whether a captive insurance structure could fit your group before costs force a harder decision.
Key details
Viking's path to a $92 stock price depends on trial results and launch timing.
Eli Lilly's stock has topped a trillion dollars, raising questions about buying now.
A new whitepaper says captive insurance could give employers sustainable GLP-1 coverage.
A UK study found Ozempic and Wegovy users had nearly 40 percent fewer asthma attacks.
A Connecticut drugmaker has partnered to develop an inhaled weight-loss treatment.
Originally published on GLP-1 Nation.
Every Sunday, the weekly newsletter pulls the full week together: the news from GLP-1 Nation, the access updates from GLP1Laws, the latest GLP-1 Studio podcast episodes, and what changed in the Cozy Butter community.